RAPIDIRON试验:口服铁剂与单剂静脉铁剂治疗妊娠期缺铁性贫血及降低低出生体重儿的三臂随机对照试验
RAPIDIRON是一项在印度开展的三臂随机对照试验,旨在比较妊娠中期单剂静脉铁剂与标准口服铁剂治疗中度缺铁性贫血的效果。研究主要结局为孕30-34周或分娩前血红蛋白恢复至妊娠正常水平的比例,以及低出生体重(<2500g)分娩风险。该试验将为单剂静脉铁剂是否更有效且经济可行地降低妊娠期缺铁性贫血提供证据。
要点
- 印度孕妇贫血率超过50%,现有口服铁剂方案因副作用和依从性差影响疗效。
- RAPIDIRON试验比较两种单剂静脉铁剂与标准口服铁剂在孕中期治疗中度缺铁性贫血的效果。
- 主要结局包括孕30-34周或分娩前血红蛋白正常比例及低出生体重(<2500g)分娩风险。
核心结论
- RAPIDIRON试验将提供证据以确定单剂静脉铁剂输注是否比当前标准治疗更有效且经济可行地减少妊娠期缺铁性贫血。
研究设计与样本
- 三臂随机对照试验,设计效能可报告两个主要结局。
- 在妊娠中期对中度缺铁性贫血孕妇给予单剂两种不同静脉铁剂制剂,与标准剂量口服铁剂比较。
关键数值与推荐
- 第一个主要结局:孕30-34周或分娩前达到妊娠正常血红蛋白浓度的参与者百分比。
- 第二个主要结局:低出生体重(<2500g)分娩,假设静脉铁剂组风险低于口服铁剂组。
- 印度国家家庭健康调查显示超过50%孕妇患贫血。
- 印度Anaemia Mukt Bharat强化国家铁加计划目标为育龄妇女、青少年和儿童贫血患病率每年降低3%,并促进实现2025年全球世界卫生大会目标:育龄妇女贫血减少50%。
- NFHS-5调查(2020年完成)初步结果表明一些邦贫血率上升,上述目标不太可能实现。
临床怎么用
- 为妊娠期缺铁性贫血治疗中单剂静脉铁剂与口服铁剂的选择提供比较证据。
- 关注静脉铁剂对低出生体重分娩风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anaemia is a worldwide problem and iron deficiency is the most common cause. In pregnancy, anaemia increases the risk of adverse maternal, foetal and neonatal outcomes. India's anaemia rate is among the highest in the world with India's National Family Health Survey indicating over 50% of pregnant women were affected by anaemia. India's Anaemia Mukt Bharat-Intensified National Iron Plus Initiative aims to reduce the prevalence of anaemia among reproductive-age women, adolescents and children by 3% per year and facilitate the achievement of a Global World Health Assembly 2025 objective to achieve a 50% reduction of anaemia among women of reproductive age. However, preliminary results of the NFHS-5 survey completed in 2020 indicate that anaemia rates are increasing in some states and these targets are unlikely to be achieved. With oral iron being the first-line treatment for iron deficiency anaemia (IDA) in pregnancy, these results are likely to be impacted by the side effects, poor adherence to tablet ingestion and low therapeutic impact of oral iron. These reports suggest a new approach to treating IDA, specifically the importance of single-dose intravenous iron infusions, may be the key to India effectively reaching its targets for anaemia reduction. METHODS: This 3-arm, randomized controlled trial is powered to report two primary outcomes. The first is to assess whether a single dose of two different intravenous formulations administered early in the second trimester of pregnancy to women with moderate IDA will result in a higher percentage of participants achieving a normal for pregnancy Hb concentration at 30-34 weeks' gestation or just prior to delivery when compared to participants taking standard doses of oral iron. The second is a clinical outcome of low birth weight (LBW) (< 2500 g), with a hypothesis that the risk of LBW delivery will be lower in the intravenous iron arms when compared to the oral iron arm. DISCUSSION: The RAPIDIRON trial will provide evidence to determine if a single-dose intravenous iron infusion is more effective and economically feasible in reducing IDA in pregnancy than the current standard of care. TRIAL REGISTRATION: Clinical Trials Registry - India CTRI/2020/09/027730. Registered on 10 September 2020, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=46801&EncHid=&userName=anemia%20in%20pregnancy.
引用
- Derman RJ, Goudar SS, Thind S, et al. RAPIDIRON: Reducing Anaemia in Pregnancy in India-a 3-arm, randomized-controlled trial comparing the effectiveness of oral iron with single-dose intravenous iron in the treatment of iron deficiency anaemia in pregnant women and reducing low birth weight deliveries. Trials. 2021. PMID: 34556166. doi:10.1186/s13063-021-05549-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。